Skip to main content

Syndicate contentEli Lilly and Company

Landmark survey highlights needs of unpaid caregivers of people with diabetes

Chevy Chase, MD -- The Hormone Foundation, the public education affiliate of The Endocrine Society, in collaboration with the National Alliance for Caregiving, today released key findings from a first-of-its-kind survey (http://www.hormone.org/Public/diabetes_caregiver.cfm) aimed at better understa

Report offers principles for maintaining the integrity and accessibility of research data

WASHINGTON -- Though digital technologies and high-speed communications have significantly expanded the capabilities of scientists -- allowing them to analyze and share vast amounts of data -- these technologies are also raising difficult questions for researchers, institutions, and journals.

UCLA scientists present first genetic evidence for why placebos work

Placebos are a sham -- usually mere sugar pills designed to represent "no treatment" in a clinical treatment study. The effectiveness of the actual medication is compared with the placebo to determine if the medication works.

Inhaled growth hormone safe for children deficient in this key protein

INDIANAPOLIS -- A multi-center clinical trial led by a Riley Hospital for Children endocrinologist has found that inhaled growth hormone (GH) is well tolerated by children with GH deficiency and that this easy-to-use method can, over a one-week period, safely deliver GH to the blood stream.

Exenatide promotes weight loss when added to diet and exercise

In combination with diet and exercise, the diabetes drug exenatide helped nondiabetic, obese individuals lose over three times more weight than those receiving a placebo, or dummy treatment, for 6 months. The results of the new study will be presented Thursday at The Endocrine Society's 91st Annual Meeting in Washington, D.C.

Erectile dysfunction treatments do not appear to damage vision over 6 months

Two medications used to treat erectile dysfunction in men (tadalafil and sildenafil) do not appear to have visual side effects when taken daily for six months, despite concerns about eye-related complications, according to a report in the April issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

Test quickly assesses whether Alzheimer's drugs are hitting their target

A test developed by physician-scientists at Washington University School of Medicine in St. Louis may help assess more quickly the ability of Alzheimer's drugs to affect one of the possible underlying causes of Alzheimer's disease in humans, accelerating the development of new treatments.



About us

Science Blog was started in August 2002. It lives, breathes and eats press releases from research organizations around the globe. Most of what you read here are press releases from the outfits named in the stories themselves. Got a news story you think belongs here? Let's talk. The other half of the equation is blog posts from readers like you. So if you have an interest in science, please register and join others like you in an ongoing, vibrant dialog about what makes the world tick. Meantime, please take a minute to read our Privacy Policy and Site Disclaimer.


Premium Drupal Themes by Adaptivethemes